GlassScriptPhysician profile
Rodolfo Rodriguez
NPI 1437198009
$243,629.74
in general payments reported to CMS, 2019-2025
25 companies · $100K in 2025
The $100K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $7,715 · 2021: $7,792 · 2022: $28K · 2023: $28K · 2024: $61K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $50K · Travel and Lodging: $25K · Food and Beverage: $9,734 · Consulting Fee: $9,475 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,183.19 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $49,900.00 |
| Travel and Lodging | $25,495.46 |
| Food and Beverage | $9,734.03 |
| Consulting Fee | $9,475.00 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $94,292.92 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Tarsus Pharmaceuticals, INC. | $61,226.38 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $33,572.95 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Oyster Point Pharma, INC. | $21,017.88 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $17,510.63 | 2022-2025 | Tryptyr, Eysuvis, Rocklatan |
| Allergan, INC. | $12,475.08 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $927.07 | 2019-2022 | |
| Abbvie INC. | $742.20 | 2022-2025 | Lumigan |
| Eyevance Pharmaceuticals LLC | $337.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $285.76 | 2019-2023 | |
| Genzyme Corporation | $185.94 | 2023-2024 | |
| Dompe US, INC. | $183.96 | 2021-2025 | Oxervate |
| Biotissue Holdings INC. | $127.98 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $121.12 | 2019-2021 | |
| Sight Sciences, INC. | $118.41 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $95.57 | 2019 | |
| Harrow Eye, LLC | $82.89 | 2024-2025 | Vevye |
| Coopervision INC. | $81.37 | 2021-2025 | Misight Contact Lens |
| Horizon Therapeutics Plc | $75.97 | 2023 | Tepezza |
| Shire North American Group INC | $55.39 | 2019 | |
| Optos, INC. | $29.42 | 2019 | |
| Aerie Pharmaceuticals, INC. | $27.47 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $19.73 | 2025 | Acthar |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.